Media

The CannaMoms at Steep Hill

DSC_0297
cannamoms
Yesterday we had the opportunity to host the CannaMoms at our Oakland, CA laboratory.

We would like to send out a huge thank to the CannaMoms and their children for traveling from Florida to learn more about medical cannabis. It was both humbling and insightful seeing cannabis science meet treatment for the critically ill, particularly in such delicate and controversial circumstances.

Topics covered included information about the dangers and safety issues of using cannabis to treat critically ill children, medical efficacy, terpenoids, cannabinoids and decarboxylation, dosing, extraction methods and preparation of medicines, and further resources.

About CannaMoms:

This group of passionate mothers advocates for the right and option to utilize cannabis in the care of their critically ill children. They fight diligently for common sense legislation, and have spent tireless hours informing the public of the medicinal benefits of cannabis while raising awareness of the need for more compassionate, effective, and safer options for children with critical illnesses. They believe their personal hardships and experiences lend them the knowledge required to help other parents of critically ill children, and they spend much of their time out of the public eye working one-on-one with parents nationwide:

“Our mission is to perpetuate compassion and give power back to the people. Don’t just stand on the sideline… get engaged in your community today!”
www.thecannamoms.com

cannamoms 1
cannamoms 2
cannamoms 3
cannamoms 4
cannamoms 5
cannamoms 6

Steep Hill Labs Announces Release of QuantaCann2

PRESS RELEASE
Oakland, Ca – Today, Steep Hill Labs, Inc. announced the release of its highly anticipated, next generation cannabis testing technology, the QuantaCann2. “We are excited that the QuantaCann2 is now available for lease in all states where legal cannabis markets exist,” said CEO and Co-Founder David Lampach. “Our advanced optical platform and cloud-based analytics can deliver laboratory-grade THC, CBD and moisture test results anywhere in the world in under 60 seconds.”

QuantaCann2 is the world’s first remote, on-site instant potency and process analysis technology that enables business users such as cannabis producers, processors, dispensaries, other testing labs and even regulators to have real-time access to chemical information for their raw materials and products at their own locations. The platform aggregates information from Steep Hill’s world-leading database of test results and other proprietary resources, using a sophisticated, proprietary SaaS interface and analytical models. The QuantaCann2 scans the source material using near-infrared spectrometry and sends the spectral scans through the cloud for analytical processing. Results are delivered through the QC2’s unique user interface, providing instant, conclusive potency and moisture data to users, dynamically and virtually.

“The time has come to make sure that the potency and active ingredient profile of cannabis available in the consumer marketplace is known, and transparent. By democratizing access to sophisticated potency testing, the QuantaCann2 is an important tool for the cannabis industry in the effort to maximize product safety and consumer knowledge,” emphasized Lampach in making the announcement. QuantaCann2’s testing functions, processes, and a modified version of its user interface were featured in Sunday night’s episode of CBS’s CSI: Crime Scene Investigation, entitled “Buzz Kill.”

“We are pleased that CSI chose our QuantaCann2 technology to help solve the crime in ’Buzz Kill.’ As the nation’s leading provider of cannabis testing, analytics and quality management solutions for the burgeoning industry, the acknowledgement and validation that comes from such prominent media recognition is an honor,” said Lampach. “Identifying unique strains of cannabis and matching them to a large database is not only possible in helping to solve a crime on television, it is actually already possible in real life today through Steep Hill’s technological innovations such as the QuantaCann2.”

For more information on how to lease a QuantaCann2, please visit http://steephilllab.com/quantacann/ or call 510-562-7400 to speak with a Steep Hill representative.

ABOUT STEEP HILL LABS, INC.
Founded in Oakland, CA, in 2008, Steep Hill is a science and technology firm that has become the industry leader in cannabis testing and analytics in the United States, and internationally. Steep Hill pioneered the first medical cannabis potency and microbiological contaminants testing methodology used in California, which was the first state to legalize medical cannabis. The company has since developed a variety of revolutionary cannabis industry testing products, including the QuantaCann, and now the QuantaCann2. Steep Hill has also provided expert consulting advice to many U.S. states and local municipalities on effective cannabis testing, quality assurance and regulation for a healthy and safe supply of medical cannabis.

For more information please visit www.steephilllab.com

QuantaCann2 on CSI: Buzz Kill


Air date: Oct 5, 2014
Full episode: www.cbs.com

HIGH TIMES U.S. Cannabis Cup panels, WA 2014

Canna-business 101: How to open yours (09/07/2014)

• Jen Bernstein (moderator), HIGH TIMES
Adam Mintz, Steep Hill Halent
• Garyn Angel, Magical Butter
• Brett Albanese, Cloud Penz.
• Kitty Dunleavy Miller, Cannabis Farmers Markets, Kit-Tea’s Herbal Remedies
• Aaron Justis, Buds & Roses LA, Kushman Veganics
 

The Science of Cannabis: Understanding Our Medicine (09/06/2014)

Adam Mintz (moderator), Steep Hill Halent
Rev. Dr. Kymron deCesare, Steep Hill Halent
• Dr. Benson Hausman, Elemental Wellness Center
 

The New Washington Apple: Navigating i502 (09/06/2014)

• Kurt Boehl (moderator), criminal defense attorney
• Adam Smith, Avitas Agriculture
• Michael Devlin, consumer goods professional
• Lauren Downes, Herbal Nation
• James Lathrop, Cannabis City
Adam Mintz, Steep Hill Halent

CBN: A Sleeping Synergy

cbn1
Many who have heard of the cannabinoid Cannabinol (CBN) have a negative impression of the compound, as it is typically believed to be a degraded compound that appears in old, poorly stored cannabis. However, this bleak perspective is not entirely accurate.

Unlike most cannabinoids, CBN rarely results from the decarboxylation of its acid form (CBNA). Most of the CBN found in cannabis is due to the degradation of THC, wherein the THC has oxidized to CBN.

CBN is either non-psychoactive or very mildly psychoactive. It reduces intraocular pressure in the eye (similar to D9THC), so it can be used in the treatment of Glaucoma without the psychoactive effects of THC. CBN is synergistic with THC for treatment purposes. CBN also fights free radicals in the bloodstream, and it performs similarly to THC in pain reduction treatments.

Of all the cannabinoids, CBN appears to be the most sedative. Not only is it sedative, it takes very little to do the job. The consumption of 2.5mg to 5mg of CBN has the same level of sedation as a mild pharmaceutical sedative, with a relaxed body sensation similar to 5mg to 10mg of diazepam. CBN is synergistic with both CBD and D9THC for inducement of sleeping, and when mixed in the correct ratios, CBN becomes an effective sleep aid of 5-6 hours duration.

As we do more research focused on CBN, we will no doubt discover more fascinating properties of this often misunderstood cannabinoid. In the meantime, CBN appears to be a beneficial alternative to THC for treatment, and patients that require low (or no) adverse psychoactive effects.

tangie-cookies-oil

GC (decarboxylate) cannabinoid profile of Tangie Cookies Oil sample with noteable CBN concentrations

Download full PDF report — Tangie Cookies Oil

Read more — Indica or Sativa: Here’s How to Know

REFERENCE CITATIONS:
Lemberger, L., and H. Rowe. “Clinical pharmacology of nabilone, a cannabinol derivative.” Clinical pharmacology and therapeutics 18.06 (1975): 720-726.
Boissier, J. R. “Clinical pharmacological study and eeg changes of delta-9 tetrahydro-cannabinol effects in human volunteers.” Biochemical Pharmacology23 (1974): 751-755.